Magnetic resonance spectroscopy and schizophrenia: What have we learnt?

Australian and New Zealand Journal of Psychiatry

Volumn 34, Issue 1, 2000, Pages 14-25

  Vance, Alasdair L A ^a   Velakoulis, Dennis ^a   Maruff, Paul ^a   Wood, Stephen J ^a   Desmond, Patricia ^a   Pantelis, C ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Integration; Magnetic resonance spectroscopy; Review; Schizophrenia

Indexed keywords

ARTICLE; BIOCHEMISTRY; BRAIN DYSFUNCTION; BRAIN NERVE CELL; BRAIN REGION; CELL MEMBRANE; CELL VOLUME; CONTROLLED STUDY; DEGRADATION; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; METHODOLOGY; NERVE CELL DIFFERENTIATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREFRONTAL CORTEX; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; THEORY;

BRAIN; BRAIN MAPPING; ENERGY METABOLISM; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034583111     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2000.00702.x     Document Type: Article

References (84)

1. Imaging as a tool in exploring the neurodevelopment and genetics of schizophrenia
2. A historical review of NMR and its clinical applications
3. Nuclear induction
4. Resonance absorption by nuclear magnetic moments in a solid
5. Magnetic resonance spectroscopy and functional MRI
6. Magnetic resonance spectroscopy in psychiatry: Potential, pitfalls, and promise
7. Nuclear magnetic resonance spectroscopy: A review of neuropsychiatric applications
8. Magnetic resonance imaging
9. Magnetic resonance spectroscopy
10. In vivo magnetic resonance spectroscopy
11. Magnetic resonance spectroscopy in psychiatry: Basic principles and applications
12. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy
13. Proton magnetic resonance spectroscopy: An in vivo method of estimating hippocampal neuronal depletion in Schizophrenia
14. 31P magnetic resonance Spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique - Preliminary findings
15. 31Phosphrous magnetic resonance spectrosopy of the dorsolateral prefrontal region in schizophrenia - A study including 50 patients and 36 controls
16. 31P-MRS, of the human brain in the study of schizophrenia
17. 31P. Nuclear magnetic resonance spectroscopy. Neurodevelopment and schizophrenia
18. Clinical applications of magnetic resonance spectroscopy
19. Alterations of membrane phospholipid metabolism in patients with schizophrenia assessed by phosphorous magnetic resonance spectroscopy
20. 31P magnetic resonance spectroscopy studies in schizophrenia
21. Neurochemical studies of schizophrenia in Japan
22. Magnetic resonance spectroscopy in schizophrenia: A nascent technology for a neurodevelopmental disorder?
23. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism
24. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?
25. Implications of normal brain development for the pathogenesis of schizophrenia
26. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naïve schizophrenics
27. Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia
28. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorous magnetic resonance spectroscopy
29. Magnetic resonance imaging volumetric and Phosphorous 31 magnetic resonance spectroscopy measurements in schizophrenia
30. Localised Phosphorous 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls
31. 31P-MR spectroscopy study
32. Lateralised abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorous-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia
33. 31Phosphrous magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia
34. 1H decoupling of medicated schizophrenics and healthy controls
35. 31P-magnetic resonance spectroscopic study
36. Fronto-striatal cognitive deficits in patients with chronic schizophrenia
37. Anteromedial temporo-prefrontal connectivity: A functional neuroanatomical system implicated in schizophrenia
38. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: A magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins
39. 31P magnetic resonance chemical shift imaging
40. 31P-MRS and MRI studies
41. 31P-magnetic resonance spectroscopy
42. −31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia
43. The brief psychiatric rating scale
44. Correlation between left frontal phospholipids and Wisconsin card sort test performance in schizophrenia
45. High energy phosphates in the frontal lobe correlate with the Wisconsin card sort test performance in controls, not in schizophrenics: A 31-phosphorous magnetic resonancespectroscopic and neuropsychological investigation
46. 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia
47. Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms
48. 31P magnetic resonance spectroscopy
49. Cognitive deficits in schizophrenia and Parkinson's disease: Neural basis and the role of dopamine
50. Neurocognitive and neurobehavioural patterns and the syndromes of schizophrenia: Role of frontal-subcortical networks
51. Is the concept of frontal-subcortical dementia relevant to schizophrenia?
52. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types
53. Metabolism and role of glutamate in mammalian brain
54. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy
55. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia
56. 1H-Magnetic resonance spectrosopy of the left temporal and frontal lobes in schizophrenia: Clinical, neurodevelopmental and cognitive correlates
57. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia
58. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging
59. Frontal lobe of children with schizophrenia spectrum disorders: A proton magnetic resonance spectroscopic study
60. Regionally specific neuronal pathology in untreated patients with schizophrenia: A proton magnetic resonance spectroscopic imaging study
61. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging
62. Neuropsychophysiological study of children at risk for schizophrenia: A preliminary report
63. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients
64. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy
65. Hippocampal volume reducation in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study
66. Smaller hippocampi in chronic schizophrenia and first-episode schizophrenia and affective psychoses: A high resolution magnetic resonance imaging study
67. Proton magnetic resonance spectroscopy of the hippocampal formation in schizophrenia: A pilot study
68. Hippocampal age-related changes in schizophrenia: A proton magnetic resonance spectroscopy study
69. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy
70. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: Preliminary report
71. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis
72. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls
73. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype
74. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood
75. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia
76. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: A preliminary report
77. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients
78. 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia
79. 19F-nuclear magnetic resonance-spectroscopy
80. 19F nuclear magnetic resonance spectroscopy of neuroleptics: The first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain
81. 19F nuclear magnetic resonance spectroscopy study
82. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: Preliminary studies
83. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia
84. Integrating qualitative and quantitative methods in the study of developmental psychopathology in context